**Core Concept**
The patient has been diagnosed with chronic hepatitis C virus (HCV) infection, which can lead to liver fibrosis, cirrhosis, or hepatocellular carcinoma if left untreated. The presence of antibodies to HCV indicates a past or ongoing infection.

**Why the Correct Answer is Right**
In this scenario, the patient has been exposed to HCV for 6 months, and his liver enzymes (AST/ALT) are within normal limits. The absence of symptoms or stigmata of liver disease suggests that the patient may be in the early stages of infection or has a favorable host response. The most appropriate approach is to initiate antiviral therapy with direct-acting antivirals (DAAs), which have revolutionized the treatment of HCV and can achieve high cure rates (defined as sustained virologic response, SVR) with minimal side effects.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because waiting for the development of liver disease or symptoms may lead to advanced fibrosis or cirrhosis, making treatment more challenging and less effective.
* **Option B:** This option is incorrect because liver biopsy is not the first-line approach in this scenario, and it carries risks such as bleeding and pain.
* **Option C:** This option is incorrect because interferon-based therapy has been largely replaced by DAAs due to their improved efficacy and tolerability.

**Clinical Pearl / High-Yield Fact**
It is essential to note that all patients with chronic HCV infection should be tested for HIV, hepatitis B virus (HBV), and hepatitis D virus (HDV) to assess their overall liver disease burden and to guide treatment decisions.

**Correct Answer: C. Initiate antiviral therapy with direct-acting antivirals (DAAs).**